Differentiation, differentiation/gene therapy and cancer.

[1]  R. Scott,et al.  Differentiation modulates the balance of positive and negative Jun/AP-1 DNA binding activities to regulate cellular proliferative potential: different effects in nontransformed and transformed cells , 1996, The Journal of cell biology.

[2]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[3]  Z. Su,et al.  The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. , 1995, Oncogene.

[4]  Y. Fujiwara,et al.  Vascular endothelial cell lineage-specific promoter in transgenic mice. , 1995, Development.

[5]  H. Klein,et al.  Cellular gene therapy. , 1995, Hematology/oncology clinics of North America.

[6]  J. Mulé,et al.  Gene therapy: current status and future prospects , 1994, Journal of leukocyte biology.

[7]  R. Weber,et al.  13-cis-retinoic acid plus interferon-α2a in recurrent respiratory papillomatosis , 1994 .

[8]  R. Scott,et al.  Adipocyte differentiation selectively represses the serum inducibility of c-jun and junB by reversible transcription-dependent mechanisms. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[10]  S. Yuspa.  The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis--thirty-third G. H. A. Clowes Memorial Award Lecture. , 1994, Cancer research.

[11]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Ponnazhagan,et al.  Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors , 1994, The Journal of experimental medicine.

[13]  T. Fujiwara,et al.  Gene therapeutics and gene therapy for cancer. , 1994, Current opinion in oncology.

[14]  M. Bolla,et al.  Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. , 1994, European journal of cancer.

[15]  A. Roth,et al.  13-cis-retinoic acid plus interferon-alpha: a phase II clinical study in squamous cell carcinoma of the lung and the head and neck. , 1994, Oncology.

[16]  S. Mineishi,et al.  Gene therapy utilizing drug resistance genes: A review , 1994, Stem cells.

[17]  S. Lippman,et al.  Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. , 1994, Leukemia.

[18]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[19]  R. Recker,et al.  Long‐standing remission after 25‐OH D3 treatment in a case of chronic myelomonocytic leukaemia , 1993, British journal of haematology.

[20]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[21]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[22]  S. Rosenberg,et al.  The Development of Gene Therapy for the Treatment of Cancer , 1993, Annals of surgery.

[23]  J. Roth,et al.  A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. , 1993, Cancer research.

[24]  E. Borden,et al.  Differentiation therapy of cancer: laboratory and clinical investigations. , 1993, Cancer research.

[25]  M Buyse,et al.  Adjuvant treatment of stage I lung cancer with high-dose vitamin A. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Fuchs,et al.  Probing keratinocyte and differentiation specificity of the human K5 promoter in vitro and in transgenic mice , 1993, Molecular and cellular biology.

[27]  S. Galvin,et al.  A 300 bp 5'-upstream sequence of a differentiation-dependent rabbit K3 keratin gene can serve as a keratinocyte-specific promoter. , 1993, Journal of cell science.

[28]  F. Mandelli,et al.  Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. , 1993, Leukemia.

[29]  S. Lippman,et al.  Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Roth,et al.  Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. , 1993, Cancer research.

[31]  S. Sell,et al.  The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. , 1993, The International journal of developmental biology.

[32]  S. Lippman,et al.  Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer. , 1993, Anti-cancer drugs.

[33]  L. Donehower,et al.  Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. , 1993, Human gene therapy.

[34]  S. Lippman,et al.  Retinoic acid and interferon combination studies in human cancer. , 1993, European journal of cancer.

[35]  R. Scott,et al.  Induction of c-jun independent of PKC, pertussis toxin-sensitive G protein, and polyamines in quiescent SV40-transformed 3T3 T cells. , 1992, Experimental cell research.

[36]  M. Raffeld,et al.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer , 1992, The Journal of experimental medicine.

[37]  I. Pastan,et al.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.

[38]  B. Cheson,et al.  Retinoids in cancer therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Vedantham,et al.  Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. , 1992, Cancer research.

[40]  S. Tapscott,et al.  Functional antagonism between c-Jun and MyoD proteins: A direct physical association , 1992, Cell.

[41]  A. Asher,et al.  Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. , 1992, Human gene therapy.

[42]  R. Scott,et al.  Selective induction of c-jun and jun-B but not c-fos or c-myc during mitogenesis in SV40-transformed cells at the predifferentiation growth arrest state. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[43]  Zi X. Chen,et al.  A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. , 1991, Blood.

[44]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[45]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[46]  R. Scott,et al.  Insulin‐induced mitogenesis associated with transformation by the SV40 large T antigen , 1991, Journal of cellular physiology.

[47]  Robert K. Davis,et al.  The myoD gene family: nodal point during specification of the muscle cell lineage. , 1991, Science.

[48]  K. Cornetta,et al.  Safety issues related to retroviral-mediated gene transfer in humans. , 1991, Human gene therapy.

[49]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[50]  S. Kliewer,et al.  Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor , 1990, Cell.

[51]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[52]  A. Khwaja,et al.  Isoquinolinesulfonamide protein kinase inhibitors H7 and H8 enhance the effects of granulocyte-macrophage colony-stimulating factor (GM-CSE) on neutrophil function and inhibit GM-CSF receptor internalization. , 1990, Blood.

[53]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[54]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[55]  C. Tzen,et al.  Three distinct effects of SV40 T‐antigen gene transfection on cellular differentiation , 1990, Journal of cellular physiology.

[56]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  R. Scott,et al.  Loss of proliferative potential during terminal differentiation coincides with the decreased abundance of a subset of heterogeneous ribonuclear proteins , 1989, The Journal of cell biology.

[58]  R. Scott,et al.  Nonterminally differentiated cells express decreased growth factor responsiveness , 1989, Journal of cellular physiology.

[59]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[60]  G. Gahrton,et al.  Therapeutic effects of low‐dose cytosine arabinoside, alpha‐interferon, 1α‐hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes , 1988, European journal of haematology.

[61]  M. Pittelkow,et al.  Biologic mechanisms for the regulation of normal human keratinocyte proliferation and differentiation. , 1988, The American journal of pathology.

[62]  S. Waxman,et al.  The status of differentiation therapy of cancer , 1988 .

[63]  N. Colburn,et al.  Growth factors, tumor promoters and cancer genes , 1988 .

[64]  R. Clark,et al.  A randomized trial of 13‐cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome , 1987, British journal of haematology.

[65]  L. Pfeffer,et al.  Interferons α and β as cellular regulatory MOLECULES , 1987 .

[66]  W. Hong,et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.

[67]  R. Scott,et al.  Aproliferin--a human plasma protein that induces the irreversible loss of proliferative potential associated with terminal differentiation. , 1986, The American journal of pathology.

[68]  R. Scott,et al.  Suppression of tumorigenicity by the cell‐cycle‐dependent control of cellular differentiation and proliferation , 1986, International journal of cancer.

[69]  R. Scott,et al.  Regulation of the terminal event in cellular differentiation: biological mechanisms of the loss of proliferative potential , 1986, The Journal of cell biology.

[70]  H. Koeffler,et al.  1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. , 1985, Cancer treatment reports.

[71]  R. Scott,et al.  Defective control of terminal differentiation and its role in carcinogenesis in the 3T3 T proadipocyte stem cell line. , 1985, Cancer research.

[72]  R. Scott,et al.  An initiator of carcinogenesis selectively and stably inhibits stem cell differentiation: a concept that initiation of carcinogenesis involves multiple phases. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[73]  G. Church,et al.  B lineage--specific interactions of an immunoglobulin enhancer with cellular factors in vivo. , 1985, Science.

[74]  J. Griffin,et al.  Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. , 1983, The New England journal of medicine.

[75]  R. Scott,et al.  Differential mitogenic effects of methyl isobutyl xanthine and a tumor growth factor on G1-arrested 3T3 T proadipocytes at the predifferentiation GD state and the growth-factor deficiency GS state. , 1983, Experimental cell research.

[76]  R. Scott,et al.  Coupling of proadipocyte growth arrest and differentiation. II. A cell cycle model for the physiological control of cell proliferation , 1982, The Journal of cell biology.

[77]  M. Housset,et al.  Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells? , 1982, British journal of haematology.

[78]  A. Schechter,et al.  Induction of hemoglobin accumulation in human K562 cells by hemin is reversible. , 1981, Science.

[79]  J. Rheinwald,et al.  Defective terminal differentiation in culture as a consistent and selectable character of malignant human keratinocytes , 1980, Cell.

[80]  L. Sachs.  Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia: a model for the origin and progression of malignancy. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[81]  G. Saunders.  Cell differentiation and neoplasia , 1978 .

[82]  H. Green,et al.  An established preadipose cell line and its differentiation in culture II. Factors affecting the adipose conversion , 1975, Cell.

[83]  W. Scher,et al.  Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[84]  H. Holtzer.  PROLIFERATIVE AND QUANTAL CELL CYCLES IN THE DIFFERENTIATION OF MUSCLE, CARTILAGE, AND RED BLOOD CELLS* , 1970 .